Which Peptides Are Legal to Compound in 2026? Complete Category Guide | Peptadex

Understanding Peptide Legality in 2026

Navigating the legal peptide landscape in 2026 is confusing, and for good reason. Between the ongoing FDA Category reclassification, the GLP-1 compounding wars, and the gray market for research chemicals, the rules depend entirely on context. This guide breaks down which peptides are legal for compounding, what the categories mean, and where things stand as of April 2026.

FDA-Approved Peptide Drugs

These peptides have full FDA approval as pharmaceutical products and are available through standard pharmacies with a prescription:

• Semaglutide (Ozempic, Wegovy, Rybelsus) -- approved for T2D, obesity, and cardiovascular risk reduction
• Tirzepatide (Mounjaro, Zepbound) -- approved for T2D and obesity
• Liraglutide (Victoza, Saxenda) -- approved for T2D and obesity
• Exenatide (Byetta, Bydureon) -- approved for T2D
• Dulaglutide (Trulicity) -- approved for T2D
• Orforglipron (Foundayo) -- approved April 2026 for obesity, the first oral non-peptide GLP-1 agonist
• Icotrokinra (Icotyde) -- approved March 2026 for plaque psoriasis
• Tesamorelin (Egrifta) -- approved for HIV-associated lipodystrophy
• Setmelanotide (Imcivree) -- approved for genetic obesity disorders
• Bremelanotide (Vyleesi) -- approved for hypoactive sexual desire disorder

Category 1 Peptides: Legal for Compounding

Category 1 substances can be legally compounded by licensed 503A and 503B pharmacies under a physician's prescription. These are NOT FDA-approved drugs, but compounding them is permitted within regulatory guidelines.

Peptides that have historically maintained Category 1 status include various amino acid compounds, bioidentical hormones, and certain research peptides. The specific list is maintained by the FDA and updated periodically.

Category 2 Peptides: Currently Restricted (Pending Reclassification)

Category 2 substances are flagged by the FDA as having potential safety concerns or insufficient characterization data. Compounding these carries significant legal risk for pharmacies.

In February 2026, HHS Secretary Kennedy announced that approximately 14 of 19 Category 2 peptides would be reclassified to Category 1. The peptides expected to be reclassified include:

Peptide	Primary Use Category	Expected New Status
BPC-157	Healing/Recovery	Category 1 (pending)
Thymosin Alpha-1	Immune Support	Category 1 (pending)
TB-500	Recovery/Repair	Category 1 (pending)
CJC-1295	Growth Hormone	Category 1 (pending)
Ipamorelin	Growth Hormone	Category 1 (pending)
AOD-9604	Fat Loss	Category 1 (pending)
Selank	Cognitive/Anxiety	Category 1 (pending)
Semax	Cognitive	Category 1 (pending)
KPV	Immune/Gut Health	Category 1 (pending)
MOTS-c	Longevity/Metabolism	Category 1 (pending)

Critical caveat: As of April 2026, the formal FDA reclassification has NOT been published in the Federal Register. The legal status of these peptides technically remains Category 2 until that formal publication occurs.

The GLP-1 Compounding Question

Compounding of semaglutide and tirzepatide occupies a separate legal battleground. During official drug shortages, compounding pharmacies can legally compound copies of FDA-approved drugs. With the end of semaglutide shortage declarations, Novo Nordisk has moved aggressively against compounding pharmacies producing semaglutide. Eli Lilly has taken similar stances regarding tirzepatide.

The legality of compounded GLP-1 agonists depends on current shortage status, pharmacy licensure type, and ongoing litigation outcomes. This situation is rapidly evolving.

Research Chemicals: A Legal Gray Area

Many online peptide vendors sell products labeled "for research purposes only" or "not for human consumption." These products exist in a regulatory gray area. While purchasing research chemicals is not inherently illegal, administering them to humans without FDA approval or a valid compounding pathway raises legal and safety concerns.

Key Takeaways

• FDA-approved peptide drugs (semaglutide, tirzepatide, orforglipron, etc.) are legally available through standard prescriptions.
• Category 1 peptides can be legally compounded by licensed pharmacies under a physician's prescription.
• Fourteen Category 2 peptides are expected to be reclassified to Category 1, but formal FDA publication remains pending as of April 2026.
• GLP-1 compounding legality depends on drug shortage status and is subject to ongoing litigation.
• Research chemical purchases exist in a legal gray area and carry quality and safety risks when used for human administration.

Disclaimer: This article is for educational and informational purposes only. It does not constitute legal advice. Peptide regulations are subject to rapid change. Always consult a qualified healthcare provider and verify current regulations with the FDA or a legal professional before pursuing any peptide therapy. Peptadex does not sell peptides or endorse any specific products or vendors.